BAKER BROS. ADVISORS LP: BEONE MEDICINES LTD. (ONC): Quarterly 13F Position History
As of Q1 2026, BAKER BROS. ADVISORS LP reported 8,799,053 shares of BEONE MEDICINES LTD. (ONC), worth $2.6B and representing 15.0% of its 13F equity book. The position first appeared in Q1 2016 and has been disclosed across 41 13F-HR filings in Pactolio's tracked window.
- 8,799,053Shares Held (Latest Filing)
- $2.6BReported Market Value (Latest Filing)
- 15.0%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$60.2MQuarter-over-Quarter Value Change
- 13,301,597Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,799,053 | 0 | — | $2.6B | 15.0% | $297.0 |
| Q4 2025 | 8,799,053 | 0 | — | $2.7B | 15.7% | $303.8 |
| Q3 2025 | 8,799,053 | 0 | — | $3.0B | 21.7% | $340.7 |
| Q2 2025 | 8,799,053 | 0 | — | $2.1B | 20.7% | $242.1 |
| Q1 2025 | 8,799,053 | 732,827 | -7.7% | $2.4B | 26.5% | $272.2 |
| Q4 2024 | 9,531,880 | 1,037,017 | -9.8% | $1.8B | 18.8% | $184.7 |
| Q3 2024 | 10,568,897 | 0 | — | $2.4B | 24.6% | $224.5 |
| Q2 2024 | 10,568,897 | 0 | — | $1.5B | 19.3% | $142.7 |
| Q1 2024 | 10,568,897 | 0 | — | $1.7B | 20.7% | $156.4 |
| Q4 2023 | 10,568,897 | 1,100,000 | -9.4% | $1.9B | 21.7% | $180.4 |
| Q3 2023 | 11,668,897 | 0 | — | $2.1B | 12.1% | $179.9 |
| Q2 2023 | 11,668,897 | 0 | — | $2.1B | 12.0% | $178.3 |
| Q1 2023 | 11,668,897 | 0 | — | $2.5B | 13.7% | $215.5 |
| Q4 2022 | 11,668,897 | 0 | — | $2.6B | 15.4% | $219.9 |
| Q3 2022 | 11,668,897 | 0 | — | $1.6B | 10.3% | $134.8 |
| Q2 2022 | 11,668,897 | 0 | — | $1.9B | 10.7% | $161.8 |
| Q1 2022 | 11,668,897 | 0 | — | $2.2B | 12.6% | $188.6 |
| Q4 2021 | 11,668,897 | 0 | — | $3.2B | 15.4% | $270.9 |
| Q3 2021 | 11,668,897 | 0 | — | $4.2B | 18.6% | $363.0 |
| Q2 2021 | 11,668,897 | 0 | — | $4.0B | 17.6% | $343.2 |
| Q1 2021 | 11,668,897 | 0 | — | $4.1B | 17.6% | $348.1 |
| Q4 2020 | 11,668,897 | 1,632,700 | -12.3% | $3.0B | 11.4% | $258.4 |
| Q3 2020 | 13,301,597 | +1,524,312 | +12.9% | $3.8B | 15.2% | $286.4 |
| Q2 2020 | 11,777,285 | 0 | — | $2.2B | 9.8% | $188.4 |
| Q1 2020 | 11,777,285 | 0 | — | $1.4B | 8.9% | $123.1 |
| Q4 2019 | 11,777,285 | 0 | — | $2.0B | 10.4% | $165.8 |
| Q3 2019 | 11,777,285 | 0 | — | $1.4B | 9.8% | $122.5 |
| Q2 2019 | 11,777,285 | 182,539 | -1.5% | $1.5B | 9.9% | $124.0 |
| Q1 2019 | 11,959,824 | 0 | — | $1.6B | 10.1% | $132.0 |
| Q4 2018 | 11,959,824 | 0 | — | $1.7B | 13.7% | $140.3 |
| Q3 2018 | 11,959,824 | 0 | — | $2.1B | 13.6% | $172.2 |
| Q2 2018 | 11,959,824 | +6,130,395 | +105.2% | $1.8B | 13.8% | $153.7 |
| Q1 2018 | 5,829,429 | +1,980,198 | +51.4% | $979.3M | 8.3% | $168.0 |
| Q4 2017 | 3,849,231 | 49,200 | -1.3% | $376.1M | 3.3% | $97.7 |
| Q3 2017 | 3,898,431 | +225,256 | +6.1% | $403.3M | 3.3% | $103.5 |
| Q2 2017 | 3,673,175 | 0 | — | $165.3M | 1.4% | $45.0 |
| Q1 2017 | 3,673,175 | 0 | — | $134.5M | 1.1% | $36.6 |
| Q4 2016 | 3,673,175 | +1,760,495 | +92.0% | $111.5M | 1.1% | $30.4 |
| Q3 2016 | 1,912,680 | 0 | — | $58.9M | 0.5% | $30.8 |
| Q2 2016 | 1,912,680 | 0 | — | $57.0M | 0.6% | $29.8 |
| Q1 2016 | 1,912,680 | — | — | $56.1M | 0.6% | $29.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a ONC position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported BEONE MEDICINES LTD. (ONC) on its 13F-HR filing for the period ending 2016-03-31 (Q1 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in ONC?
BAKER BROS. ADVISORS LP held the same 8,799,053 shares of ONC between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in ONC?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.